Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FERMT2 | Q96AC1 | 4/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.76 |
| ▸ | HTT | P42858 | 1/20 | 0.76 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.76 |
| ▸ | CCR1 | P32246 | 1/20 | 0.72 |
| ▸ | CDK1 | P06493 | 1/20 | 0.63 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15483264 | 1.00 | FERMT2 (0.76) | FERMT2KDM4ELMNAHTTHSD17B10 | |
| Hydrochloric Acid SCHEMBL22616749 | 0.99 | FERMT2 (0.74) | FERMT2KDM4ELMNAHTTHSD17B10 | |
| Hydrochloric Acid SCHEMBL13737549 | 0.99 | FERMT2 (0.74) | FERMT2KDM4ELMNAHTTHSD17B10 | |
| SCHEMBL15483265 | 0.99 | FERMT2 (0.74) | FERMT2KDM4ELMNAHTTHSD17B10 | |
| SCHEMBL23640942 | 0.95 | FERMT2 (0.81) | FERMT2KDM4ELMNAHTTHSD17B10 | |
| SCHEMBL17921786 | 0.95 | FERMT2 (0.70) | FERMT2KDM4ELMNAHTTHSD17B10 | |
| SCHEMBL17921846 | 0.94 | FERMT2 (0.72) | FERMT2KDM4ELMNAHTTHSD17B10 | |
| SCHEMBL17921785 | 0.94 | FERMT2 (0.72) | FERMT2KDM4ELMNAHTTHSD17B10 | |
| SCHEMBL17527056 | 0.93 | FERMT2 (0.67) | FERMT2KDM4ELMNAHTTHSD17B10 | |
| SCHEMBL22735553 | 0.93 | FERMT2 (0.67) | FERMT2KDM4ELMNAHTTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024179420-A1 | USE OF LYS01 OR SALT THEREOF IN PREPARATION OF KIR4.1 POTASSIUM CHANNEL INHIBITOR | 中国科学院上海药物研究所 | 2024-09-06 | — | — | WO | claimed |
| CN-118576596-A | Application of Lys01 or salt thereof in preparation of Kir4.1 potassium ion channel inhibitor | 中国科学院上海药物研究所 | 2024-09-03 | — | — | CN | claimed |
| US-20220323376-A1 | METHODS AND COMPOSITIONS FOR SENSITIZING CANCER CELLS TO DRUG-INDUCED APOPTOSIS | NEW YORK UNIVERSITY | 2022-10-13 | — | — | US | claimed |
| CN-111908970-B | Preparation method of coal gangue microbial fertilizer | 贵州大学 | 2022-05-20 | — | — | CN | claimed |
| CN-111893074-B | Bacillus fusiformis strain and application thereof | 贵州大学 | 2022-05-20 | — | — | CN | claimed |
| CN-120158468-A | Construction method and application of escherichia coli engineering strain for improving yield of L-lysine by using ethylene glycol | 元素驱动(杭州)生物科技有限公司 | 2025-06-17 | — | — | CN | disclosed |
| US-12303508-B2 | Combinatory treatment strategies of cancer based on RNA polymerase I inhibition | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-05-20 | — | — | US | disclosed |
| EP-4470560-A1 | TUMOR IMMUNOTHERAPY | Pingshan Translational Medicine Center, Shenzhen Bay Laboratory (CN) | 2024-12-04 | — | — | EP | disclosed |
| WO-2024179420-A1 | USE OF LYS01 OR SALT THEREOF IN PREPARATION OF KIR4.1 POTASSIUM CHANNEL INHIBITOR | 中国科学院上海药物研究所 | 2024-09-06 | — | — | WO | disclosed |
| WO-2024179420-A1 | USE OF LYS01 OR SALT THEREOF IN PREPARATION OF KIR4.1 POTASSIUM CHANNEL INHIBITOR | 中国科学院上海药物研究所 | 2024-09-06 | — | — | WO | disclosed |
| WO-2024179420-A1 | USE OF LYS01 OR SALT THEREOF IN PREPARATION OF KIR4.1 POTASSIUM CHANNEL INHIBITOR | 中国科学院上海药物研究所 | 2024-09-06 | — | — | WO | disclosed |
| CN-118576596-A | Application of Lys01 or salt thereof in preparation of Kir4.1 potassium ion channel inhibitor | 中国科学院上海药物研究所 | 2024-09-03 | — | — | CN | disclosed |
| EP-3515448-B1 | COMBINATORY TREATMENT STRATEGIES OF CANCER BASED ON RNA POLYMERASE I INHIBITION | UNIV JOHNS HOPKINS (US) | 2023-07-05 | — | — | EP | disclosed |
| US-11639335-B2 | Asymmetric bisaminoquinolines and bisaminoquinolines with varied linkers as autophagy inhibitors for cancer and other therapy | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2023-05-02 | — | — | US | disclosed |
| US-11591298-B2 | Bisaminoquinoline compounds, pharmaceutical compositions prepared therefrom and their use | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2023-02-28 | — | — | US | disclosed |
| US-20220323376-A1 | METHODS AND COMPOSITIONS FOR SENSITIZING CANCER CELLS TO DRUG-INDUCED APOPTOSIS | NEW YORK UNIVERSITY | 2022-10-13 | — | — | US | disclosed |
| CN-111893074-B | Bacillus fusiformis strain and application thereof | 贵州大学 | 2022-05-20 | — | — | CN | disclosed |
| CN-111893074-B | Bacillus fusiformis strain and application thereof | 贵州大学 | 2022-05-20 | — | — | CN | disclosed |
| CN-111908970-B | Preparation method of coal gangue microbial fertilizer | 贵州大学 | 2022-05-20 | — | — | CN | disclosed |
| CN-111908970-B | Preparation method of coal gangue microbial fertilizer | 贵州大学 | 2022-05-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11591298-B2 | Bisaminoquinoline compounds, pharmaceutical compositions prepared therefrom and their use | SQSTM1, UACA, ATG7 | FERMT2 4659/4885KDM4E 1512/4885LMNA 2676/4885 |
| US-11639335-B2 | Asymmetric bisaminoquinolines and bisaminoquinolines with varied linkers as autophagy inhibitors for cancer and other therapy | SQSTM1, ATG7, BECN1 | FERMT2 3692/4885KDM4E 1279/4885LMNA 1633/4885 |
| US-20220323376-A1 | METHODS AND COMPOSITIONS FOR SENSITIZING CANCER CELLS TO DRUG-INDUCED APOPTOSIS | MCL1, BAX, CASP3 | FERMT2 3301/4885KDM4E 4152/4885LMNA 514/4885 |
| US-12303508-B2 | Combinatory treatment strategies of cancer based on RNA polymerase I inhibition | ACAT1, PARP1, POLRMT | FERMT2 3724/4885KDM4E 2864/4885LMNA 2273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.